- Shares of Sarepta Therapeutics (SRPT -7.1%) are down sharply in morning trading.
- The catalyst for the move looks to be an article by SA contributor EnhydrisPECorp who, according to the disclosure statements, was long SRPT last month and is now short.
- Essentially, the piece attacks the small sample size of the eteplirsen Phase 2 trial and questions if it was appropriate (from a statistical perspective) to deem two patients outliers for the purpose of evaluating ambulatory performance even though they demonstrated "dramatic increases in dystrophin production."
- Incidentally, SA contributor Steven Breazzano also published a bearish piece on SRPT today.
at Zacks.com (Nov 13, 2014)